BTIG analyst David Larsen raised the firm’s price target on Medline (MDLN) to $55 from $50 and keeps a Buy rating on the shares following the JP Morgan Healthcare Conference. The company provided a high-level overview for those who were new to the business, including highlights of its two key segments Medline Brand and Supply Chain Solutions, the analyst tells investors in a research note. BTIG is positive on the way Medline serves the entire healthcare continuum, and its Prime Vendor relationships are sticky, with a 98% retention rate.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Top 3 Trending Stocks, According to Analysts – 1/15/2026
- 2 New IPO Stocks Hit the Market – Morgan Stanley Picks the Superior One to Buy
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Opening Day: Aktis Oncology raises $318M in 2026’s first biotech IPO
- Medline initiated with a Buy at Citi